Real-World Evidence on the Efficacy and Durability of Novel Therapies for nAMD, DME, and RVO
home / state-of-sciences-presentations / real-world-evidence-on-the-efficacy-and-durability-of-novel-therapies-for-namd-dme-and-rvo
Retina specialists come together to share key insights from multiple patient cases, highlighting how novel therapies like faricimab and aflibercept 8 mg have improved durability and patient outcomes in neovascular AMD, DME, and RVO.
